INTRODUCTION
Leptomeningeal metastases (LM) occur when cancer cells invade the pia mater, arachnoid mater, subarachnoid space, and cerebrospinal fluid of the central nervous system. [1] e incidence of clinically diagnosed LM in patients with solid tumors is approximately 5%, but the incidence of undiagnosed or asymptomatic LM may be as high as 20% or more in certain solid tumors, as confirmed by autopsy series. [11] By primary cancer type, LM are most commonly found in with breast cancer, representing 12%-35% of cases. [1, 11] Frequency of LM is 5% in the whole breast cancer. [11] e prognosis of LM is poor, and survival in untreated patients is short with periods of only 4-6 weeks reported. [11] e main forms of antitumor treatment are radiotherapy, mainly by means of whole-brain radiotherapy, and intrathecal chemotherapy. However, even with active treatment, survival remains <8 months on average, and the development of new treatment options and the establishment of a standard therapy are both urgent tasks. [11] Herein, we report a case of the patient with LM from human epidermal growth factor receptor 2 (HER2)-positive breast cancer who responded well to systemic chemotherapy with lapatinib plus capecitabine.
CASE PRESENTATION
A 46-year-old woman had undergone mastectomy for breast cancer (estrogen receptor 2+, progesterone receptor 3+, and HER2 3+) 5 years before presentation and had subsequently remained under observation without any postoperative adjuvant therapy. Multiple lung, liver, and bone metastases were identified in year 3 postoperatively, and systemic chemotherapy was introduced. e chemotherapy regimen included docetaxel, trastuzumab, pertuzumab, and bisphosphonates, and radiotherapy for lumbar spinal bone metastases (20 Gy/5 Fr). However, she developed multiple brain metastases (BM) 1 year later, which were treated with whole-brain radiotherapy (30 Gy/10 Fr) and placement of a ventriculoperitoneal shunt for hydrocephalus. e systemic chemotherapy regimen was subsequently switched to trastuzumab emtansine, but further LM developed, and the patient was referred to our hospital.
At the time of referral, Eastern Cooperative Oncology Group (ECOG) performance status was 4, level of consciousness as assessed by Glasgow coma scale score was E3V4M6, and she was suffering from intractable headaches, severe nausea and vomiting, and cerebellar ataxia. T1-weighted gadoliniumenhanced magnetic resonance imaging (MRI) revealed diffuse contrast enhancement of the meninges, mainly in the posterior cranial fossa, with compression of the cerebellum by the significantly thickened meninges [ Figure 1a ,b]. In light of the clinical course, treatment options were limited, and best supportive care was presented as an option.
However, the patient requested further therapy, and given her good karnofsky performance status (KPS), an aggressive treatment strategy was pursued. e first step in the treatment was to relieve intracranial hypertension, and decompression of the posterior cranial fossa was performed [ Figure 2 ]. After surgery, headaches, nausea, and vomiting were immediately improved and her performance status improved.
Treatment with lapatinib at 1250 mg and capecitabine 1200 mg was started on postoperative day 14. As early as 2 weeks later, the diffuse abnormal signal enhancement across her tissues shrunk dramatically on T1-weighted gadoliniumenhanced MRI after starting this new regimen [ Figure 3a ,b]. Further imaging revealed that the LM had almost disappeared on MRI by 2 months of therapy [ Figure 3c ,d]. At present, no recurrence has been observed more than 1 year after the treatment. e patient is continuing to attend our hospital unit for treatment under the same regimen and currently remains well with an ECOG Performance Status 1.
DISCUSSION
Recently, a number of cases have been reported of BM responding to systemic chemotherapy, particularly using molecular-targeted drugs. With lung cancer treatment, good therapeutic outcomes have been reported with the use of molecular-targeted drugs not only for BM but also for LM. [4, 5, 7, 10] As a result, we are now in an era when the central nervous system may also be a target of systemic chemotherapy. In breast cancer treatment, a number of regimens have been explored; several agents are under investigation. [12] Trastuzumab is now available for HER2-positive patients, in hopes that this agent might also have antitumor effects on the central nervous system. However, the high molecular weight of this agent means that it cannot easily pass through the blood-brain barrier, and this treatment has not proven effective for tumors of the central nervous system.
{6]
Lapatinib has now succeeded trastuzumab as a new drug targeting HER2 and epidermal growth factor receptor, and its low molecular weight compared with trastuzumab gives support to the notion of greater efficacy against central nervous system lesions. We have reported herein a case in which LM responded well to combination therapy with lapatinib plus capecitabine. Although our patient had undergone decompression surgery to relieve symptoms of intracranial hypertension, the effects were certainly expected to be temporary only, and hence the second step treatment with lapatinib plus capecitabine was added. e effects of this combination of chemotherapy were rapidly apparent, and a good outcome for the patient was achieved.
e response rate with lapatinib monotherapy for recurrent BM after treatment with trastuzumab and radiotherapy is 2.6%-6.0% and this rate is further improved in combination therapy with capecitabine. [8, 9] e LANDSCAPE study, a Phase 2 trial of lapatinib plus capecitabine combination therapy for BM, achieved good therapeutic outcomes, with a tumor regression rate ≥50% obtained in 65.9% of patients and the median time to central nervous system progression of 5.5 months. [2] e response assessment in a neuro-oncology working group recently proposed guidelines for the diagnosis and response assessment of LM. [3] e treatment result for LM using these evaluation criteria will be reported in the future. As a result, new therapeutic strategies for LM seem highly likely to be developed.
CONCLUSION
We treated a patient with LM from primary HER2-positive breast cancer who responded well to lapatinib plus capecitabine.
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